The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | P | Antiparasitic products, insecticides and repellents | |
| 2 | P01 | Antiprotozoals | |
| 3 | P01C | Agents against leishmaniasis and trypanosomiasis | |
| 4 | P01CC | Nitrofuran derivatives | |
| 5 | P01CC01 | Nifurtimox |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.7 g |
| Active Ingredient | Description | |
|---|---|---|
| Nifurtimox |
Nifurtimox is an antiprotozoal drug. It is used in pediatric patients for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi. Nifurtimox exposure-response relationships and the time course of pharmacodynamics response are unknown. |
